公开(公告)号：US20240238327A1

公开(公告)日：2024-07-18

申请号：US17915943

申请日：2022-02-28

申请人： RENATUS INC.

发明人： Hee Gon KIM

IPC分类号： A61K31/724 ,  A61K31/195 ,  A61K38/26 ,  A61P3/06

CPC分类号： A61K31/724 ,  A61K31/195 ,  A61K38/26 ,  A61P3/06

摘要： Provided are: a pharmaceutical composition including a gamma-cyclodextrin-based polymer, for prevention and treatment of diseases related to cholesterol metabolism dysregulation; and use thereof. The pharmaceutical composition including a gamma-cyclodextrin polymer for prevention or treatment of diseases related to cholesterol metabolism dysregulation, according to an embodiment, by including the gamma-cyclodextrin-based polymer, may minimize extraction of plasma membrane cholesterol and thus not cause cytotoxicity and hemolytic activity, thereby facilitating intracellular metabolism and excretion of cholesterol, and effectively suppressing the secretion of IL-1β, MCP-1, and TNF-α cytokines, thereby exhibiting an excellent anti-inflammatory effect.

公开(公告)号：US11931376B1

公开(公告)日：2024-03-19

申请号：US18314962

申请日：2023-05-10

申请人： RENATUS INC.

发明人： Hee Gon Kim

IPC分类号： A61K31/724 ,  A61P13/12

CPC分类号： A61K31/724 ,  A61P13/12

摘要： Provided are a method of treating chronic kidney disease or one or more symptoms thereof, or reducing a complication related to chronic kidney disease, the method comprising, administering a therapeutically effective amount of gamma-cyclodextrin oligomer to a subject in need thereof. The gamma-cyclodextrin oligomers are effective in cholesterol metabolism enhancement, cholesterol efflux, reducing inflammatory cytokine secretion, renal clearance of cholesterol and/or reducing albuminuria. Therefore, the gamma-cyclodextrin oligomers can be used to treat or alleviate chronic kidney disease, symptoms thereof and/or a complication related to chronic kidney disease.

公开(公告)号：US20240148779A1

公开(公告)日：2024-05-09

申请号：US18484111

申请日：2023-10-10

申请人： RENATUS INC.

发明人： Hee Gon KIM

IPC分类号： A61K31/724 ,  A61P25/28 ,  A61P29/00

CPC分类号： A61K31/724 ,  A61P25/28 ,  A61P29/00

摘要： Provided is a method of i) preventing or reducing protein aggregation, ii) reducing protein deposition, iii) reducing cytotoxicity induced by protein aggregation or deposition or deposition, or iv) alleviating or reducing inflammation induced by protein aggregation or deposition in an individual, wherein the method comprises administering a therapeutically effective amount of a pharmaceutical composition including a gamma-cyclodextrin oligomer to the individual, thereby preventing or reducing protein aggregation, reducing protein deposition, reducing cytotoxicity induced by protein aggregation or deposition, or alleviating or reducing inflammation induced by protein aggregation or deposition in the individual diagnosed with, suspected to have, or at risk of developing proteinopathy.